Symbols / AUTL
AUTL Chart
About
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 487.39M |
| Enterprise Value | 442.15M | Income | -224.80M | Sales | 51.13M |
| Book/sh | 1.00 | Cash/sh | 1.38 | Dividend Yield | — |
| Payout | 0.00% | Employees | 647 | IPO | — |
| P/E | — | Forward P/E | -2.20 | PEG | — |
| P/S | 9.53 | P/B | 1.84 | P/C | — |
| EV/EBITDA | -1.67 | EV/Sales | 8.65 | Quick Ratio | 5.52 |
| Current Ratio | 6.19 | Debt/Eq | 122.50 | LT Debt/Eq | — |
| EPS (ttm) | -0.83 | EPS next Y | -0.83 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-19 | ROA | -22.99% |
| ROE | -60.56% | ROIC | — | Gross Margin | -264.79% |
| Oper. Margin | -3.38% | Profit Margin | 0.00% | Shs Outstand | 266.14M |
| Shs Float | 84.34M | Short Float | 7.64% | Short Ratio | 6.30 |
| Short Interest | — | 52W High | 2.70 | 52W Low | 1.10 |
| Beta | 1.99 | Avg Volume | 2.69M | Volume | 1.21M |
| Target Price | $8.99 | Recom | Strong_buy | Prev Close | $1.82 |
| Price | $1.83 | Change | 0.62% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.99
Mean price target
2. Current target
$1.83
Latest analyst target
3. DCF / Fair value
$-18.11
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.83
Low
$5.00
High
$13.00
Mean
$8.99
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-17 | init | HC Wainwright & Co. | — → Buy | $9 |
| 2026-01-12 | main | Needham | Buy → Buy | $10 |
| 2025-12-29 | main | Needham | Buy → Buy | $11 |
| 2025-12-12 | reit | Needham | Buy → Buy | $10 |
| 2025-11-03 | reit | Needham | Buy → Buy | $10 |
| 2025-10-20 | reit | Needham | Buy → Buy | $10 |
| 2025-08-13 | main | Wells Fargo | Overweight → Overweight | $5 |
| 2025-07-21 | reit | Needham | Buy → Buy | $10 |
| 2025-06-12 | reit | Needham | Buy → Buy | $10 |
| 2025-04-10 | reit | Needham | Buy → Buy | $10 |
| 2025-04-01 | main | Truist Securities | Buy → Buy | $10 |
| 2025-03-21 | main | Wells Fargo | Overweight → Overweight | $6 |
| 2025-01-13 | reit | Needham | Buy → Buy | $10 |
| 2024-12-09 | reit | Needham | Buy → Buy | $10 |
| 2024-12-05 | reit | Needham | Buy → Buy | $10 |
| 2024-11-18 | up | Goldman Sachs | Neutral → Buy | $8 |
| 2024-11-15 | up | Redburn Atlantic | Neutral → Buy | $13 |
| 2024-11-13 | reit | Needham | Buy → Buy | $10 |
| 2024-11-12 | main | Needham | Buy → Buy | $10 |
| 2024-11-11 | reit | Needham | Buy → Buy | $9 |
- Biotech Autolus lines up TD Cowen, Jefferies investor events in March - Stock Titan ue, 24 Feb 2026 12
- The Market Doesn't Like What It Sees From Autolus Therapeutics plc's (NASDAQ:AUTL) Revenues Yet As Shares Tumble 26% - simplywall.st ue, 03 Feb 2026 08
- Autolus Therapeutics Plc (AUTL) Stock Analysis: A Biotech Gem With 606% Potential Upside - DirectorsTalk Interviews Fri, 06 Feb 2026 13
- How Investors Are Reacting To Autolus Therapeutics (AUTL) Trimming Losses and Appointing a New Finance Chief - Yahoo Finance hu, 13 Nov 2025 08
- AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK - Stocktwits ue, 25 Nov 2025 08
- Autolus: Good Product, But Tricky Market Dynamics (Rating Downgrade) (NASDAQ:AUTL) - Seeking Alpha Sat, 01 Nov 2025 07
- Inside the push to automate production of a leukemia cell therapy - Stock Titan ue, 06 Jan 2026 08
- Is Autolus Therapeutics PLC (AUTL) One of the Fastest-Growing Penny Stocks to Buy Now? - Yahoo Finance Mon, 24 Nov 2025 08
- Autolus Therapeutics (AUTL) Stock Analysis: A Biotech With 541% Potential Upside - DirectorsTalk Interviews Fri, 24 Oct 2025 07
- Spotlight On Silence Therapeutics And 2 Other Promising Penny Stocks - simplywall.st hu, 19 Feb 2026 11
- Autolus (Nasdaq: AUTL) to Launch AUCATZYL on NHS in England and Wales After NICE Backing - Stock Titan ue, 25 Nov 2025 08
- Is Autolus Therapeutics plc (AUTL) The Best Get Rich Fast Stocks to Buy Right Now? - Yahoo Finance Sat, 27 Dec 2025 08
- Autolus Therapeutics plc (AUTL) Stock Analysis: Exploring a 472.75% Potential Upside in T Cell Therapy Innovation - DirectorsTalk Interviews Fri, 17 Oct 2025 07
- A Fresh Look at Autolus Therapeutics (AUTL) Valuation Following Earnings, Obe-cel Expansion, and Anticipated ASH Data - simplywall.st Sat, 15 Nov 2025 08
- Autolus (Nasdaq: AUTL) moves obe-cel into Phase 2 LUMINA lupus nephritis trial - Stock Titan Mon, 08 Dec 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -341.46K | -139.85 | -108.15K | -182.52K |
| TaxRateForCalcs | 0.21 | 0.00 | 0.21 | 0.27 |
| NormalizedEBITDA | -200.50M | -155.24M | -131.72M | -131.80M |
| TotalUnusualItems | -1.63M | -1.53M | -515.00K | -676.00K |
| TotalUnusualItemsExcludingGoodwill | -1.63M | -1.53M | -515.00K | -676.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -220.66M | -208.38M | -148.84M | -142.10M |
| ReconciledDepreciation | 7.72M | 6.57M | 7.42M | 8.46M |
| ReconciledCostOfRevenue | 11.39M | 0.00 | ||
| EBITDA | -202.12M | -156.77M | -132.24M | -132.47M |
| EBIT | -209.84M | -163.34M | -139.66M | -140.93M |
| NetInterestIncome | 23.06M | -31.56M | -7.20M | -843.00K |
| InterestExpense | 9.29M | 45.07M | 8.90M | 1.10M |
| InterestIncome | 32.35M | 13.51M | 1.71M | 262.00K |
| NormalizedIncome | -219.38M | -206.85M | -148.43M | -141.60M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -220.66M | -208.38M | -148.84M | -142.10M |
| TotalExpenses | 250.91M | 177.23M | 149.09M | 141.88M |
| TotalOperatingIncomeAsReported | -241.43M | -179.70M | ||
| DilutedAverageShares | 255.16M | 173.94M | 94.99M | 72.08M |
| BasicAverageShares | 255.16M | 173.94M | 94.99M | 72.08M |
| DilutedEPS | -0.86 | -1.20 | -1.57 | -1.97 |
| BasicEPS | -0.86 | -1.20 | -1.57 | -1.97 |
| DilutedNIAvailtoComStockholders | -220.66M | -208.38M | -148.84M | -142.10M |
| NetIncomeCommonStockholders | -220.66M | -208.38M | -148.84M | -142.10M |
| NetIncome | -220.66M | -208.38M | -148.84M | -142.10M |
| NetIncomeIncludingNoncontrollingInterests | -220.66M | -208.38M | -148.84M | -142.10M |
| NetIncomeContinuousOperations | -220.66M | -208.38M | -148.84M | -142.10M |
| TaxProvision | 1.53M | -19.00K | 272.00K | 58.00K |
| PretaxIncome | -219.13M | -208.40M | -148.57M | -142.04M |
| OtherIncomeExpense | -1.41M | -1.31M | 1.52M | -821.00K |
| OtherNonOperatingIncomeExpenses | 220.00K | 222.00K | 2.04M | -145.00K |
| SpecialIncomeCharges | -637.00K | -4.17M | -515.00K | -676.00K |
| GainOnSaleOfPPE | -223.00K | -3.79M | -515.00K | -676.00K |
| ImpairmentOfCapitalAssets | 414.00K | 382.00K | 0.00 | 0.00 |
| GainOnSaleOfSecurity | -989.00K | 2.64M | ||
| NetNonOperatingInterestIncomeExpense | 23.06M | -31.56M | -7.20M | -843.00K |
| InterestExpenseNonOperating | 9.29M | 45.07M | 8.90M | 1.10M |
| InterestIncomeNonOperating | 32.35M | 13.51M | 1.71M | 262.00K |
| OperatingIncome | -240.79M | -175.53M | -142.89M | -140.37M |
| OperatingExpense | 239.52M | 177.23M | 149.09M | 141.88M |
| OtherOperatingExpenses | -166.00K | -823.00K | ||
| ResearchAndDevelopment | 138.44M | 130.48M | 117.35M | 110.84M |
| SellingGeneralAndAdministration | 101.09M | 46.74M | 31.90M | 31.86M |
| GeneralAndAdministrativeExpense | 46.74M | 31.90M | 31.86M | |
| OtherGandA | 46.74M | 31.90M | 31.86M | |
| GrossProfit | -1.27M | 1.70M | ||
| CostOfRevenue | 11.39M | 0.00 | ||
| TotalRevenue | 10.12M | 1.70M | 6.19M | 1.51M |
| OperatingRevenue | 10.12M | 1.70M | 6.19M | 1.51M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 266.12M | 174.10M | 173.07M | 90.91M |
| ShareIssued | 266.12M | 174.10M | 173.07M | 90.91M |
| TotalDebt | 52.63M | 52.97M | 24.26M | 21.00M |
| TangibleBookValue | 414.95M | 111.47M | 298.67M | 313.25M |
| InvestedCapital | 427.32M | 111.47M | 298.67M | 313.32M |
| WorkingCapital | 600.19M | 230.56M | 379.40M | 318.40M |
| NetTangibleAssets | 414.95M | 111.47M | 298.67M | 313.25M |
| CapitalLeaseObligations | 52.63M | 52.97M | 24.26M | 21.00M |
| CommonStockEquity | 427.32M | 111.47M | 298.67M | 313.32M |
| TotalCapitalization | 427.32M | 111.47M | 298.67M | 313.32M |
| TotalEquityGrossMinorityInterest | 427.32M | 111.47M | 298.67M | 313.32M |
| StockholdersEquity | 427.32M | 111.47M | 298.67M | 313.32M |
| OtherEquityInterest | 118.00K | 118.00K | 118.00K | 118.00K |
| GainsLossesNotAffectingRetainedEarnings | -29.17M | -28.99M | -38.90M | -8.57M |
| OtherEquityAdjustments | -29.17M | -28.99M | -38.90M | -8.57M |
| RetainedEarnings | -1.10B | -878.56M | -670.18M | -521.34M |
| AdditionalPaidInCapital | 1.56B | 1.02B | 1.01B | 843.11M |
| CapitalStock | 12.00K | 8.00K | 8.00K | 4.00K |
| CommonStock | 12.00K | 8.00K | 8.00K | 4.00K |
| TotalLiabilitiesNetMinorityInterest | 355.40M | 263.91M | 191.60M | 92.24M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 294.66M | 219.17M | 145.23M | 63.69M |
| OtherNonCurrentLiabilities | 244.60M | 170.90M | 125.90M | 47.02M |
| TradeandOtherPayablesNonCurrent | 426.00K | 357.00K | 116.00K | 128.00K |
| LongTermDebtAndCapitalLeaseObligation | 49.63M | 47.91M | 19.22M | 16.55M |
| LongTermCapitalLeaseObligation | 49.63M | 47.91M | 19.22M | 16.55M |
| CurrentLiabilities | 60.74M | 44.74M | 46.37M | 28.55M |
| OtherCurrentLiabilities | 3.98M | 533.00K | 393.00K | 160.00K |
| CurrentDebtAndCapitalLeaseObligation | 3.00M | 5.05M | 5.04M | 4.45M |
| CurrentCapitalLeaseObligation | 3.00M | 5.05M | 5.04M | 4.45M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 19.68M | 14.76M | 10.18M | 8.75M |
| PayablesAndAccruedExpenses | 34.09M | 24.39M | 30.75M | 15.19M |
| CurrentAccruedExpenses | 28.52M | 24.29M | 30.22M | 14.76M |
| Payables | 5.56M | 103.00K | 531.00K | 431.00K |
| TotalTaxPayable | 3.59M | 0.00 | ||
| AccountsPayable | 1.97M | 103.00K | 531.00K | 431.00K |
| TotalAssets | 782.73M | 375.38M | 490.27M | 405.56M |
| TotalNonCurrentAssets | 121.80M | 100.08M | 64.50M | 58.61M |
| OtherNonCurrentAssets | 170.00K | 380.00K | 2.18M | 2.36M |
| NonCurrentPrepaidAssets | 963.00K | 983.00K | 1.83M | 2.04M |
| NonCurrentDeferredAssets | 3.24M | 3.06M | 2.08M | 1.83M |
| NonCurrentDeferredTaxesAssets | 3.24M | 3.06M | 2.08M | 1.83M |
| GoodwillAndOtherIntangibleAssets | 12.37M | 0.00 | 0.00 | 65.00K |
| OtherIntangibleAssets | 12.37M | 65.00K | ||
| NetPPE | 105.05M | 95.65M | 58.42M | 52.32M |
| AccumulatedDepreciation | -34.62M | -28.77M | -25.65M | -22.72M |
| GrossPPE | 139.67M | 124.43M | 84.07M | 75.03M |
| Leases | 14.12M | 12.73M | 11.69M | 14.90M |
| ConstructionInProgress | 19.64M | 12.54M | 13.19M | 2.44M |
| OtherProperties | 97.23M | 93.02M | 54.40M | 52.87M |
| MachineryFurnitureEquipment | 8.69M | 6.14M | 4.79M | 4.83M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 660.93M | 275.30M | 425.77M | 346.95M |
| OtherCurrentAssets | 1.57M | 203.00K | 240.00K | |
| CurrentDeferredAssets | 2.32M | 1.79M | 1.49M | 1.07M |
| RestrictedCash | 1.43M | 769.00K | 325.00K | 338.00K |
| PrepaidAssets | 15.21M | 8.64M | 12.34M | 8.71M |
| Inventory | 4.14M | 0.00 | ||
| FinishedGoods | 140.00K | 0.00 | ||
| WorkInProcess | 16.00K | 0.00 | ||
| RawMaterials | 3.98M | 0.00 | ||
| Receivables | 48.24M | 24.54M | 28.98M | 26.25M |
| OtherReceivables | 39.66M | 20.66M | 26.15M | 24.40M |
| TaxesReceivable | 6.00M | 2.77M | 2.70M | 1.85M |
| AccruedInterestReceivable | 2.57M | 999.00K | ||
| AccountsReceivable | 15.00K | 109.00K | 121.00K | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 588.02M | 239.57M | 382.44M | 310.34M |
| OtherShortTermInvestments | 360.64M | 0.00 | ||
| CashAndCashEquivalents | 227.38M | 239.57M | 382.44M | 310.34M |
| CashFinancial | 310.34M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -241.09M | -156.57M | -123.15M | -126.72M |
| IssuanceOfCapitalStock | 549.98M | 0.00 | 163.85M | 245.90M |
| CapitalExpenditure | -34.82M | -10.99M | -10.84M | -8.86M |
| IncomeTaxPaidSupplementalData | 2.39M | 551.00K | 471.00K | 364.00K |
| EndCashPosition | 228.81M | 240.34M | 382.76M | 310.68M |
| BeginningCashPosition | 240.34M | 382.76M | 310.68M | 154.09M |
| EffectOfExchangeRateChanges | -261.00K | 15.03M | -28.38M | -754.00K |
| ChangesInCash | -11.27M | -157.46M | 100.46M | 157.34M |
| FinancingCashFlow | 589.55M | -883.00K | 223.61M | 284.06M |
| CashFlowFromContinuingFinancingActivities | 589.55M | -883.00K | 223.61M | 284.06M |
| NetOtherFinancingCharges | 38.98M | -910.00K | 59.64M | 38.04M |
| ProceedsFromStockOptionExercised | 602.00K | 27.00K | 117.00K | 125.00K |
| NetCommonStockIssuance | 549.98M | 0.00 | 163.85M | 245.90M |
| CommonStockIssuance | 549.98M | 0.00 | 163.85M | 245.90M |
| InvestingCashFlow | -394.55M | -10.99M | -10.84M | -8.86M |
| CashFlowFromContinuingInvestingActivities | -394.55M | -10.99M | -10.84M | -8.86M |
| NetInvestmentPurchaseAndSale | -359.73M | 0.00 | ||
| PurchaseOfInvestment | -359.73M | 0.00 | ||
| NetIntangiblesPurchaseAndSale | -12.74M | 0.00 | 0.00 | |
| PurchaseOfIntangibles | -12.74M | 0.00 | 0.00 | |
| NetPPEPurchaseAndSale | -22.07M | -10.99M | -10.84M | -8.86M |
| PurchaseOfPPE | -22.07M | -10.99M | -10.84M | -8.86M |
| OperatingCashFlow | -206.27M | -145.59M | -112.31M | -117.86M |
| CashFlowFromContinuingOperatingActivities | -206.27M | -145.59M | -112.31M | -117.86M |
| ChangeInWorkingCapital | -23.66M | 292.00K | 536.00K | 410.00K |
| ChangeInOtherCurrentLiabilities | -369.00K | -13.55M | -4.69M | -2.40M |
| ChangeInOtherCurrentAssets | 3.73M | |||
| ChangeInPayablesAndAccruedExpense | 13.52M | 489.00K | 16.03M | -3.84M |
| ChangeInAccruedExpense | 11.93M | 998.00K | 16.01M | -2.02M |
| ChangeInPayable | 1.59M | -509.00K | 22.00K | -1.82M |
| ChangeInAccountPayable | 1.59M | -509.00K | 22.00K | -1.82M |
| ChangeInPrepaidAssets | -32.58M | 13.36M | -10.81M | 6.65M |
| ChangeInInventory | -4.23M | 0.00 | ||
| OtherNonCashItems | 12.51M | 49.15M | 12.32M | 4.83M |
| StockBasedCompensation | 15.47M | 11.20M | 12.01M | 9.94M |
| AssetImpairmentCharge | 414.00K | 382.00K | 0.00 | 0.00 |
| DeferredTax | -185.00K | -986.00K | -268.00K | -72.00K |
| DeferredIncomeTax | -185.00K | -986.00K | -268.00K | -72.00K |
| DepreciationAmortizationDepletion | 7.72M | 6.57M | 7.42M | 8.46M |
| DepreciationAndAmortization | 7.72M | 6.57M | 7.42M | 8.46M |
| AmortizationCashFlow | 162.00K | 0.00 | ||
| AmortizationOfIntangibles | 162.00K | 0.00 | ||
| Depreciation | 7.55M | 6.57M | ||
| OperatingGainsLosses | 2.12M | -3.81M | 4.51M | 672.00K |
| NetForeignCurrencyExchangeGainLoss | 1.90M | -7.60M | 4.00M | 0.00 |
| GainLossOnSaleOfPPE | 223.00K | 3.79M | 515.00K | 672.00K |
| NetIncomeFromContinuingOperations | -220.66M | -208.38M | -148.84M | -142.10M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for AUTL
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|